Amicus Therapeutics, Inc. $FOLD Shares Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 17.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,600 shares of the biopharmaceutical company’s stock after purchasing an additional 7,400 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Amicus Therapeutics were worth $284,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in Amicus Therapeutics in the 1st quarter valued at $30,000. PNC Financial Services Group Inc. increased its stake in shares of Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 3,497 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Amicus Therapeutics in the 1st quarter worth $53,000. GAMMA Investing LLC increased its stake in shares of Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 7,007 shares during the last quarter. Finally, 111 Capital acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter worth $77,000.

Wall Street Analyst Weigh In

A number of analysts have issued reports on FOLD shares. Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research note on Thursday, July 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Thursday, September 18th. Finally, Wall Street Zen downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.88.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $8.04 on Monday. The stock has a market cap of $2.48 billion, a PE ratio of -66.99 and a beta of 0.56. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $12.65. The stock has a fifty day simple moving average of $7.88 and a 200-day simple moving average of $6.88.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.